IL155772A0 - Piperidine mch antagonists and their use in the treatment of obesity - Google Patents
Piperidine mch antagonists and their use in the treatment of obesityInfo
- Publication number
- IL155772A0 IL155772A0 IL15577201A IL15577201A IL155772A0 IL 155772 A0 IL155772 A0 IL 155772A0 IL 15577201 A IL15577201 A IL 15577201A IL 15577201 A IL15577201 A IL 15577201A IL 155772 A0 IL155772 A0 IL 155772A0
- Authority
- IL
- Israel
- Prior art keywords
- obesity
- piperidine
- treatment
- mch antagonists
- mch
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25787300P | 2000-12-22 | 2000-12-22 | |
PCT/US2001/049301 WO2002051809A1 (en) | 2000-12-22 | 2001-12-17 | Piperidine mch antagonists and their use in the treatment of obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
IL155772A0 true IL155772A0 (en) | 2003-12-23 |
Family
ID=22978138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15577201A IL155772A0 (en) | 2000-12-22 | 2001-12-17 | Piperidine mch antagonists and their use in the treatment of obesity |
Country Status (20)
Country | Link |
---|---|
US (1) | US6472394B1 (sh) |
EP (1) | EP1343761B1 (sh) |
JP (2) | JP4025200B2 (sh) |
KR (1) | KR20040011447A (sh) |
CN (1) | CN1273451C (sh) |
AR (1) | AR031930A1 (sh) |
AT (1) | ATE302185T1 (sh) |
AU (1) | AU2002231097B2 (sh) |
CA (1) | CA2431953A1 (sh) |
DE (1) | DE60112791T2 (sh) |
ES (1) | ES2243588T3 (sh) |
HK (1) | HK1054390B (sh) |
HU (1) | HUP0302582A2 (sh) |
IL (1) | IL155772A0 (sh) |
MX (1) | MXPA03005744A (sh) |
MY (1) | MY134017A (sh) |
NZ (1) | NZ525723A (sh) |
PE (1) | PE20020658A1 (sh) |
WO (1) | WO2002051809A1 (sh) |
ZA (1) | ZA200303638B (sh) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002004433A2 (en) | 2000-07-06 | 2002-01-17 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
US6858619B2 (en) | 2001-05-04 | 2005-02-22 | Amgen Inc. | Fused heterocyclic compounds |
US6809104B2 (en) | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
IL158941A0 (en) | 2001-05-22 | 2004-05-12 | Neurogen Corp | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
US7084156B2 (en) | 2001-11-27 | 2006-08-01 | Merck & Co., Inc. | 2-Aminoquinoline compounds |
EP1465888A2 (en) | 2002-01-10 | 2004-10-13 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
WO2003060475A2 (en) | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
DE10238865A1 (de) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
AU2003285160B2 (en) * | 2002-11-06 | 2009-06-04 | Amgen Inc. | Fused heterocyclic compounds |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
JPWO2004069798A1 (ja) * | 2003-02-10 | 2006-05-25 | 萬有製薬株式会社 | ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤 |
WO2004072018A1 (ja) * | 2003-02-12 | 2004-08-26 | Takeda Pharmaceutical Company Limited | アミン誘導体 |
EP1654225A4 (en) * | 2003-08-13 | 2007-11-28 | Amgen Inc | HORMONE RECEPTOR ANTAGONISTS CONCENTRATING MELANIN |
WO2005019167A2 (en) * | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Msd株式会社 | 新規ピペリジン誘導体 |
WO2005033063A2 (en) | 2003-10-01 | 2005-04-14 | The Procter & Gamble Company | Melanin concentrating hormone antagonists |
US20060247239A1 (en) * | 2003-10-01 | 2006-11-02 | Hu Xiufeng E | Melanin concentrating hormone antagonists |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
WO2005110982A2 (en) * | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
WO2005110989A1 (en) * | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues |
DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
US7063034B2 (en) * | 2004-08-10 | 2006-06-20 | Watermark Paddlesports, Inc. | Spray skirt for watercraft |
CA2577060A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
US20090156474A1 (en) | 2004-11-01 | 2009-06-18 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
AU2006253312B2 (en) | 2005-05-30 | 2011-08-18 | Msd K.K. | Novel piperidine derivative |
CN101184753A (zh) * | 2005-05-31 | 2008-05-21 | 阿斯利康(瑞典)有限公司 | 新颖的mchr1拮抗剂以及它们用于治疗mchr1介导的病症和疾病的用途 |
US20100216758A1 (en) | 2005-08-10 | 2010-08-26 | Makoto Ando | Pyridone Compounds |
EP2330124B1 (en) | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
CA2619770A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
JP4879988B2 (ja) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体 |
CN101273026A (zh) | 2005-09-30 | 2008-09-24 | 霍夫曼-拉罗奇有限公司 | 作为mch受体拮抗剂的茚满衍生物 |
CN101291662A (zh) | 2005-10-21 | 2008-10-22 | 诺瓦提斯公司 | 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合 |
JPWO2007049798A1 (ja) | 2005-10-27 | 2009-04-30 | 萬有製薬株式会社 | 新規ベンゾオキサチイン誘導体 |
AU2006312557B2 (en) | 2005-11-10 | 2011-12-08 | Msd K.K. | Aza-substituted spiro derivative |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
JP5165586B2 (ja) * | 2005-12-28 | 2013-03-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症の処置のためのATP結合カセットトランスポーターのモジュレーターとしての、1−(ベンゾ[d][1,3]ジオキソール−5−イル)−N−(フェニル)シクロプロパン−カルボキサミド誘導体および関連化合物 |
WO2007124045A2 (en) * | 2006-04-20 | 2007-11-01 | Ampla Pharmaceuticals, Inc. | Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
CA2664358A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diarylketimine derivative |
WO2008083124A1 (en) | 2006-12-28 | 2008-07-10 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
WO2008140239A1 (en) * | 2007-05-11 | 2008-11-20 | Korea Research Institute Of Chemical Technology | Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same |
US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
JPWO2009110510A1 (ja) | 2008-03-06 | 2011-07-14 | Msd株式会社 | アルキルアミノピリジン誘導体 |
JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Msd株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010013595A1 (ja) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体 |
EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2350010B1 (en) | 2008-10-30 | 2014-03-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9840512B2 (en) | 2013-02-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
ES2901114T3 (es) | 2014-08-29 | 2022-03-21 | Tes Pharma S R L | Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa |
KR20190065312A (ko) | 2016-10-14 | 2019-06-11 | 테스 파마 에스.알.엘. | 알파-아미노-베타-카복시뮤콘산 세미알데하이드 데카복실라제의 저해제 |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
US20230018413A1 (en) | 2019-08-08 | 2023-01-19 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
WO2022040070A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Bicycloheptane pyrrolidine orexin receptor agonists |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
US6040318A (en) | 1997-06-25 | 2000-03-21 | Novo Nordisk A/S | Tricycle substituted with azaheterocyclic carboxylic acids |
AU770098B2 (en) * | 1999-02-10 | 2004-02-12 | Eli Lilly And Company | 5-HT1F agonists |
AU6503900A (en) | 1999-07-28 | 2001-02-19 | Kyowa Hakko Kogyo Co. Ltd. | Chemokine receptor antagonists and methods of use therefor |
-
2001
- 2001-12-17 CA CA002431953A patent/CA2431953A1/en not_active Abandoned
- 2001-12-17 AR ARP010105839A patent/AR031930A1/es unknown
- 2001-12-17 HU HU0302582A patent/HUP0302582A2/hu unknown
- 2001-12-17 KR KR10-2003-7008345A patent/KR20040011447A/ko not_active Application Discontinuation
- 2001-12-17 DE DE60112791T patent/DE60112791T2/de not_active Expired - Lifetime
- 2001-12-17 EP EP01991369A patent/EP1343761B1/en not_active Expired - Lifetime
- 2001-12-17 CN CNB018210066A patent/CN1273451C/zh not_active Expired - Fee Related
- 2001-12-17 IL IL15577201A patent/IL155772A0/xx unknown
- 2001-12-17 NZ NZ525723A patent/NZ525723A/en unknown
- 2001-12-17 AU AU2002231097A patent/AU2002231097B2/en not_active Ceased
- 2001-12-17 AT AT01991369T patent/ATE302185T1/de not_active IP Right Cessation
- 2001-12-17 ES ES01991369T patent/ES2243588T3/es not_active Expired - Lifetime
- 2001-12-17 US US10/023,371 patent/US6472394B1/en not_active Expired - Fee Related
- 2001-12-17 WO PCT/US2001/049301 patent/WO2002051809A1/en active IP Right Grant
- 2001-12-17 JP JP2002552906A patent/JP4025200B2/ja not_active Expired - Fee Related
- 2001-12-17 MX MXPA03005744A patent/MXPA03005744A/es active IP Right Grant
- 2001-12-18 PE PE2001001268A patent/PE20020658A1/es not_active Application Discontinuation
- 2001-12-19 MY MYPI20015748A patent/MY134017A/en unknown
-
2003
- 2003-05-12 ZA ZA200303638A patent/ZA200303638B/en unknown
- 2003-09-18 HK HK03106690.7A patent/HK1054390B/zh unknown
-
2007
- 2007-07-26 JP JP2007195250A patent/JP2007284451A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HK1054390A1 (en) | 2003-11-28 |
PE20020658A1 (es) | 2002-07-23 |
HUP0302582A2 (hu) | 2003-12-29 |
CN1481361A (zh) | 2004-03-10 |
NZ525723A (en) | 2004-11-26 |
DE60112791D1 (de) | 2005-09-22 |
JP2004516314A (ja) | 2004-06-03 |
MXPA03005744A (es) | 2003-09-05 |
JP4025200B2 (ja) | 2007-12-19 |
ES2243588T3 (es) | 2005-12-01 |
ATE302185T1 (de) | 2005-09-15 |
MY134017A (en) | 2007-11-30 |
US6472394B1 (en) | 2002-10-29 |
KR20040011447A (ko) | 2004-02-05 |
JP2007284451A (ja) | 2007-11-01 |
CN1273451C (zh) | 2006-09-06 |
HK1054390B (zh) | 2006-01-06 |
AU2002231097B2 (en) | 2004-12-09 |
ZA200303638B (en) | 2004-08-12 |
WO2002051809A1 (en) | 2002-07-04 |
DE60112791T2 (de) | 2006-06-08 |
EP1343761A1 (en) | 2003-09-17 |
AR031930A1 (es) | 2003-10-08 |
CA2431953A1 (en) | 2002-07-04 |
EP1343761B1 (en) | 2005-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL155772A0 (en) | Piperidine mch antagonists and their use in the treatment of obesity | |
HK1054225A1 (zh) | Mch拮抗劑和它們在治療肥胖中的用途 | |
IL157365A0 (en) | Mch antagonists and their use in the treatment of obesity | |
EP1541585A4 (en) | CXCR4 ANTAGONIST AND USE THEREOF | |
EP1487492A4 (en) | PREVENTION OR TREATMENT OF CANCER USING INTEGRIN ALPHAVBETA3 ANTAGONISTS COMBINED WITH OTHER AGENTS | |
EP1608318A4 (en) | CXCR4 ANTAGONISTS AND METHODS OF USE | |
HK1060727A1 (en) | Antagonists of mcp-1 function and methods of use thereof | |
HK1082690A1 (en) | Tumor necrosis factor antagonists and their use in endometriosis | |
TWI349551B (en) | Thiophenepyrimidinone derivatives and their use in therapy | |
HK1060728A1 (en) | Antagonists of mcp-1 function and methods of use thereof | |
HUP0400069A2 (hu) | Gyógyászati kombinációk és alkalmazásuk a trómbózis megelőzésére és kezelésére | |
IL159872A0 (en) | Gmg-2 polypeptides and their use | |
GB0212405D0 (en) | Composition and its therapeutic use | |
AU2002346446A8 (en) | Methods and compositions in checkpoint signaling | |
AU2002346288A8 (en) | Plypropylene fabric and its use in the personal care field | |
PL363048A1 (en) | Azabicyclic derivatives and their therapeutic use | |
HK1067664A1 (en) | The use of ribozymes in the detection of adventitious agents | |
GB0015627D0 (en) | Phosphoglycan messengers and their medical uses | |
AU2002241547A1 (en) | Mch antagonists and their use in the treatment of obesity | |
AU5104101A (en) | Composition and use | |
EP1548106A4 (en) | PROTEINS OF HUMAN ORIGIN FORMING A DOMAIN AND THEIR USE | |
GB0015623D0 (en) | Phosphoglycan messengers and their medical uses | |
GB0026428D0 (en) | Hydroimidazolone derivatives and their use in therapy | |
GB0017028D0 (en) | Peptides and their therapeutic use | |
IL163343A (en) | Use of ribozymes in the detection of adventitious agents |